Cargando…
Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
LESSONS LEARNED. Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of giant cell tumor of bone (GCTB) in this study. The efficacy could not be determined because of the small sample size. GCTB recurrences, even in the denosumab era, are still an issue; therefore, a randomi...
Autores principales: | Lipplaa, Astrid, Kroep, Judith R., van der Heijden, Lizz, Jutte, Paul C., Hogendoorn, Pancras C.W., Dijkstra, Sander, Gelderblom, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656477/ https://www.ncbi.nlm.nih.gov/pubmed/31040253 http://dx.doi.org/10.1634/theoncologist.2019-0280 |
Ejemplares similares
-
Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023) -
Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone
por: Lipplaa, Astrid, et al.
Publicado: (2019) -
Neoadjuvant denosumab for extensive giant cell tumor in os ischium —a case report
por: van der Heijden, Lizz, et al.
Publicado: (2015) -
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
por: Lipplaa, Astrid, et al.
Publicado: (2016) -
A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting
por: Sánchez‐Rovira, Pedro, et al.
Publicado: (2020)